Glenmark posts 72.2% jump in Q2 FY net profit at Rs. 610.4 Cr YoY

EBITDA was Rs. 2,359.6 crore in the quarter ended September 30, 2025

Kilitch Drugs H! FY26 PAT up 18% YoY to Rs. 10.30 Cr

Total income for the period stood at Rs. 7101.28 crore

ImmunoScape inks agreement with Cue Biopharma to launch next-gen cancer immunotherapy

The modular platform not only targets solid tumors but could also enhance traditional autologous and in vivo T cell therapies

Lupin achieves S&P Global ESG score of 91

This remarkable increase from 17 in 2021 ranks among the fastest for pharmaceutical companies, establishing Lupin as a leader in sustainable growth

Pfizer completes up to $10 billion acquisition of Metsera

Acquisition brings highly differentiated clinical-stage obesity candidates with potential to reshape the treatment landscape

Novartis opens radioligand therapy facility in Carlsbad, US

Novartis is the only pharmaceutical company with a dedicated commercial RLT portfolio

LANXESS set to showcase cutting-edge infection control solutions

LANXESS will highlight its commitment to combatting antimicrobial resistance by presenting science-based disinfection solutions

Enzymit and Cosun chart breakthrough in cell-free hyaluronic acid production

Hyaluronic acid is among the world's most valuable biopolymers, with applications spanning from dermal fillers and wound healing to drug delivery and tissue engineering

FDA approves Promega’s OncoMate test to guide personalised treatment for endometrial cancer

OncoMate MSI Dx Analysis System is a PCR-based assay designed to evaluate MSI status in tumor tissue

Lupin Manufacturing Solutions unveils dedicated oncology block at Vizag